Literature DB >> 1370686

Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils.

P Kuna1, S R Reddigari, D Rucinski, J J Oppenheim, A P Kaplan.   

Abstract

Recombinant monocyte chemotactic-activating factor (MCAF) has been shown to induce histamine release from human basophils with a dose response between 10(-9) and 10(-6) M. The peak of activity was reached at 10(-7) M. Histamine release by MCAF was rapid with an initial rate comparable with histamine release by an optimal dose of anti-IgE. MCAF led to peak histamine release within 1 min. 80% of the subjects tested were responsive to MCAF or anti-IgE, while all were responsive to FMLP. The percentage histamine release by MCAF was, however, less than that seen with anti-IgE or FMLP, but this was attributable to a lesser percent release in nonatopic subjects; atopic subjects responded similarly to all three agonists. MCAF was also shown to activate highly purified human basophils more readily than mixed leukocytes, and its activity was inhibited by a polyclonal rabbit antibody. At a suboptimal concentration (2.5 x 10(-9) M), MCAF was unable to prime the basophil to histamine release by other secretagogues. However, interleukin 3 (IL-3) and IL-5 could each prime basophils for MCAF-induced secretion. Therefore, our results suggest that MCAF may be a major contributor to the histamine-releasing activity seen in peripheral blood mononuclear cell supernatants that has been designated histamine releasing factor(s).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370686      PMCID: PMC2119123          DOI: 10.1084/jem.175.2.489

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

Review 1.  Histamine releasing factors and cytokine-dependent activation of basophils and mast cells.

Authors:  A P Kaplan; S Reddigari; M Baeza; P Kuna
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

2.  "Panning" for lymphocytes: a method for cell selection.

Authors:  L J Wysocki; V L Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

3.  Complement-mediated release of histamine from human leukocytes.

Authors:  J A Grant; E Dupree; A S Goldman; D R Schultz; A L Jackson
Journal:  J Immunol       Date:  1975-03       Impact factor: 5.422

4.  Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a.

Authors:  S C Bischoff; A L de Weck; C A Dahinden
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Relationship of one form of human histamine-releasing factor to connective tissue activating peptide-III.

Authors:  M L Baeza; S R Reddigari; D Kornfeld; N Ramani; E M Smith; P A Hossler; T Fischer; C W Castor; P G Gorevic; A P Kaplan
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  IL-8 inhibits histamine release from human basophils induced by histamine-releasing factors, connective tissue activating peptide III, and IL-3.

Authors:  P Kuna; S R Reddigari; D Kornfeld; A P Kaplan
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

Review 7.  Properties of the novel proinflammatory supergene "intercrine" cytokine family.

Authors:  J J Oppenheim; C O Zachariae; N Mukaida; K Matsushima
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

8.  Mechanism of histamine release by formyl methionine-containing peptides.

Authors:  R P Siraganian; W A Hook
Journal:  J Immunol       Date:  1977-12       Impact factor: 5.422

9.  Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line.

Authors:  C O Zachariae; A O Anderson; H L Thompson; E Appella; A Mantovani; J J Oppenheim; K Matsushima
Journal:  J Exp Med       Date:  1990-06-01       Impact factor: 14.307

10.  Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists.

Authors:  S C Bischoff; T Brunner; A L De Weck; C A Dahinden
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  30 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Mast cells. Receptors, secretagogues, and signaling.

Authors:  Bhavya B Sharma; John R Apgar; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

3.  Soluble overexpression and purification of bioactive human CCL2 in E. coli by maltose-binding protein.

Authors:  Thu Trang Thi Vu; Bon-Kyung Koo; Jung-A Song; Seon-Ha Chong; Cho Rong Park; Minh Tan Nguyen; Boram Jeong; Han-Bong Ryu; Jae Young Seong; Yeon Jin Jang; Robert Charles Robinson; Han Choe
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

Review 4.  Pro/Con debate: Is occupational asthma induced by isocyanates an immunoglobulin E-mediated disease?

Authors:  A V Wisnewski; M Jones
Journal:  Clin Exp Allergy       Date:  2010-06-07       Impact factor: 5.018

5.  Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2.

Authors:  W A Kuziel; S J Morgan; T C Dawson; S Griffin; O Smithies; K Ley; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

Review 6.  Developments in laboratory diagnostics for isocyanate asthma.

Authors:  Adam V Wisnewski
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-04

Review 7.  IgE-dependent histamine-releasing factors.

Authors:  H A Sampson; S M MacDonald
Journal:  Springer Semin Immunopathol       Date:  1993

8.  Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2.

Authors:  Zhe Ji; Zhiqin Fan; Ying Zhang; Ronghuan Yu; Haihua Yang; Chenghua Zhou; Jia Luo; Zun-Ji Ke
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

9.  Differential response of human basophils and mast cells to recombinant chemokines.

Authors:  W Füreder; H Agis; H Semper; F Keil; U Maier; M R Müller; K Czerwenka; H Höfler; K Lechner; P Valent
Journal:  Ann Hematol       Date:  1995-05       Impact factor: 3.673

10.  Protection against lethal bacterial infection in mice by monocyte-chemotactic and -activating factor.

Authors:  Y Nakano; T Kasahara; N Mukaida; Y C Ko; M Nakano; K Matsushima
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.